新闻源 财富源

2019年10月22日 星期二

誉衡药业(002437)公告正文

誉衡药业:2012年第三季度报告全文

公告日期:2012-10-29

          哈尔滨誉衡药业股份有限公司                                                    2012 年第三季度报告全文
           证券代码:002437                证券简称:誉衡药业                      公告编号:2012-063
                               哈尔滨誉衡药业股份有限公司
                                  2012 年第三季度报告全文一、重要提示
    本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性负个别及连带责任。
    所有董事均已出席了审议本次季报的董事会会议。
    公司负责人朱吉满、主管会计工作负责人杨华蓉及会计机构负责人(会计主管人员) 赵金宇声明:保证季度报告中财务报告的真实、完整。二、公司基本情况(一)主要会计数据及财务指标以前报告期财务报表是否发生了追溯调整□ 是 √ 否 □ 不适用
                                                                                         本报告期末比上年度期末增
                                    2012.9.30                      2011.12.31
                                                                                                   减(%)
    总资产(元)                         2,551,183,645.64            2,312,253,611.26                       10.33%
    归属于上市公司股东的所
                                         2,267,337,074.46            2,168,090,717.47                        4.58%
    有者权益(元)
    股本(股)                            280,000,000.00              280,000,000.00
    归属于上市公司股东的每
                                                      8.1                        7.74                        4.65%
    股净资产(元/股)
                              2012 年 7-9 月       比上年同期增减(%)      2012 年 1-9 月       比上年同期增减(%)
    营业总收入(元)             128,789,657.56                  7.76%          461,913,999.03              23.35%
    归属于上市公司股东的净
                                  21,392,999.24                  84.09%          99,246,356.99              31.44%
    利润(元)
    经营活动产生的现金流量
                                    --                      --                  175,410,535.02             333.16%
    净额(元)
    每股经营活动产生的现金
                                    --                      --                            0.63                350%
    流量净额(元/股)
    基本每股收益(元/股)                   0.08                  100%                    0.35              29.63%
    稀释每股收益(元/股)                   0.08                  100%                    0.35              29.63%
    加权平均净资产收益率
                                          0.95%                   0.4%                  4.48%                 0.9%
    (%)
    扣除非经常性损益后的加
                                          0.65%                  0.02%                  3.67%                0.01%
    权平均净资产收益率(%)扣除非经常性损益项目和金额√ 适用 □ 不适用1
           哈尔滨誉衡药业股份有限公司                                            2012 年第三季度报告全文
                                                         年初至报告期期末
                           项目                                                        说明
                                                           金额(元)
    非流动资产处置损益                                              731.09
    越权审批或无正式批准文件的税收返还、减免
    计入当期损益的政府补助(与企业业务密切相关,按
                                                                   6,000.00
    照国家统一标准定额或定量享受的政府补助除外)
    计入当期损益的对非金融企业收取的资金占用费
    企业取得子公司、联营企业及合营企业的投资成本小
    于取得投资时应享有被投资单位可辨认净资产公允价
    值产生的收益
    非货币性资产交换损益
    委托他人投资或管理资产的损益
    因不可抗力因素,如遭受自然灾害而计提的各项资产
    减值准备
    债务重组损益
    企业重组费用,如安置职工的支出、整合费用等
    交易价格显失公允的交易产生的超过公允价值部分的
    损益
    同一控制下企业合并产生的子公司期初至合并日的当
    期净损益
    与公司正常经营业务无关的或有事项产生的损益
    除同公司正常经营业务相关的有效套期保值业务外,
    持有交易性金融资产、交易性金融负债产生的公允价
    值变动损益,以及处置交易性金融资产、交易性金融
    负债和可供出售金融资产取得的投资收益
    单独进行减值测试的应收款项减值准备转回
    对外委托贷款取得的损益
    采用公允价值模式进行后续计量的投资性房地产公允
    价值变动产生的损益
    根据税收、会计等法律、法规的要求对当期损益进行
    一次性调整对当期损益的影响
    受托经营取得的托管费收入
    除上述各项之外的其他营业外收入和支出                         -68,948.00
    其他符合非经常性损益定义的损益项目                        21,460,397.76
    少数股东权益影响额                                              210.00
    所得税影响额                                              -3,104,822.77
    合计                                                      18,293,568.08             --公司对“其他符合非经常性损益定义的损益项目”以及根据自身正常经营业务的性质和特点将非经常性损益项目界定为经常性损益的项目的说明
             项目                  涉及金额(元)                             说明
    募集资金专户收益                     18,734,373.27
    理财产品收益                          2,726,024.49(二)报告期末股东总数及前十名股东持股情况表
    报告期末股东总数(户)                                                                          15,9712
          哈尔滨誉衡药业股份有限公司                                               2012 年第三季度报告全文
                                        前十名无限售条件流通股股东持股情况
                                期末持有无限售条件股份的                     股份种类及数量
            股东名称
                                          数量                        种类                      数量
    中国工商银行-博时精选股
                                               13,499,903   人民币普通股                               13,499,903
              票证券投资基金
       ORIENTAL KEYSTONE
                                               10,595,000   人民币普通股                               10,595,000
      INVESTMENT LIMITED
    中国银行-易方达医疗保健
                                                1,904,635   境内上市外资股                              1,904,635
      行业股票型证券投资基金
    中国工商银行-诺安价值增
                                                1,809,200   人民币普通股                                1,809,200
          长股票证券投资基金
    中海信托股份有限公司-浦
    江之星 11 号集合资金信托                   1,259,459   人民币普通股                                1,259,459
                         计划
    中国工商银行-诺安股票证
                                                  999,360   人民币普通股                                 999,360
                  券投资基金
    中国工商银行-诺安成长股
                                                  981,487   人民币普通股                                 981,487
           票型证券投资基金
    中国工商银行-诺安新动力
    灵活配置混合型证券投资基                      854,363   人民币普通股                                 854,363
                          金
    广发证券股份有限公司客户
                                                  649,518   人民币普通股                                 649,518
        信用交易担保证券账户
                       卫文若                     646,155   人民币普通股                                 646,155
                                未知上述股东是否存在关联关系,也未知是否属于《上市公司持股变动信息披露管理办法》
    股东情况的说明
                                中规定的一致行动人。三、重要事项(一)公司主要会计报表项目、财务指标大幅度变动的情况及原因√ 适用 □ 不适用1、2012年9月30日资产负债较期初变动较大原因说明(1)交易性金融资产增加18,300万元,增幅100%,主要是本期利用闲置资金购买短期理财产品,而上期无此事项;(2)应收票据增加336.3万元,增幅116.84%,主要因应收票据结算增加;(3)应收账款增加3,522.63万元,增长1104.94%,主要因赊销业务增加所致;(4)应收利息减少2,025万元,下降100%,应收利息已到期所致;(5)其他应收款增加3,023.93万元,增长45.13%,主要是誉衡经纬支付硫酸氢氯吡格雷总经销权意向买断金3,000万元所致;(6)在建工程增加7,976.69万元,增长56.16%,主要是募投项目投资支出增加;(7)开发支出增加1,683.65万元,增长67.28%,主要是本期增加开发阶段投入所致;(8)长期待摊费用减少61.99万元,下降51.75%,主要是费用摊销减少原值;(9)应付票据减少596.05万元,下降82.78%,主要因汇票到期支付所致;(10)预收账款增加327.12万元,增长149.76%,本期末销售预收货款增加;(11) 应付职工薪酬减少42.97万元,下降45.25%,本期末未支付的职工薪酬较上期减少;(12)应交税费减少862.99万元,下降98.45 %,主要因本期末进项税额较大,导致应交增值税下降较多;(13)其他应付款增加14,874.61万元,增长468.38%,主要因预收货物保证金10,637万元,市场推广保证金1,650万元;(14)递延所得税负债减少303.75万元,下降100 %,主要因上期预提利息收回,因此递延所得税负债转回。(15)其他流动负债增加80万元,增长134.23%,主要是广州新花城收到的广东省国家创新药物孵化基地奖励资金80万元。2、2012年1-9月损益较上年同期变动较大原因说明3
       哈尔滨誉衡药业股份有限公司                                                 2012 年第三季度报告全文(1)营业收入增加8,743.65万元,增长23.35%,主要因为销售增加所致;(2)营业税金及附加增加462.82万元,增长125.25%,主要因为本年销售收入增加所致;(3)销售费用增加5,494.99万元,增长161.95%,销售费用同比大幅度增加的主要原因是①因公司部分地区销售模式的调整以及结算方式的改变,致使差旅费、会议费、学术费、市场推广费、业务宣传费、办公费等增长较大,该项较去年同期增加3,967.20万元;②正常销售渠道费用增加为1,527.79万元,其中:A、根据公司与明治株式会社及珠海奥华的《技术使用协议》,公司于2011年4季度开始支付头孢米诺钠的技术使用费,该项销售费用较去年同期增加860.30万元; 会议费增加329万元;中介及咨询服务费增加264.09万元。(4)管理费用增加3,149.71万元,增长56.15%。管理费用同比大幅度增加的主要原因是①企业合并范围变化,增加了新花城、嘉孕投资公司,导致管理费用较上期增加444.41万元。②正常生产经营中管理费用增加2,705.3万元,主要原因为:A:科研投入加大,导致科研费用增加723.04万;B:房产税及土地使用税增加178.83万;C:职工费用增加631.39万元;D:中介服务费增加207.34万元;E:租赁费用增加463.93万元;F:业务宣传费增加243.32万元。(5)财务费用减少1,783.64万元,下降346.07%,主要是收到募集资金定期存款利息增加所致;(6)资产减值损失增加116.8万元,增长186.29%。主要因为本期计提54.1万元的资产减值损失,而上年同期为冲销62.7万元,因此导致同期对比增加116.8万元;(7)投资收益增加398.4万元,增长316.7%,主要因为:A、本期投入理财资金取得收益272.6万元;B、去年权益法核算的企业纳入合并范围,减少确认投资亏损125.8万元。(8)营业外收入减少13.92万元,下降74.48%,主要是本期收到的政府补助资金较少;(9)营业外支出减少223.23万元,下降95.31%,主要是本年对外捐赠支出减少220万元;(10)所得税费用增加770.34万元,增长51.77%,主要因为公司利润增加导致当期所得税费用增加,另外母公司上年同期所得税率12.5%,本年为15%;(11)归属于上市公司股东的净利润增加2,374.13万元,增长31.44%,主要是营业收入增长、募集资金专户定期存款利息增长实现的。3、2012年1-9月现金流量较上年同期变动较大原因说明(1)销售商品、提供劳务收到的现金增加21,130.07万元,增长49.06%,主要因本期销售收入、预收货款、预收货物保证金增加;(2)收到其他与经营活动有关的现金减少3,132.73万元,下降42.03%,主要是收回原支付药品代理权保证金本期比上期减少;(3)支付的各项税费增加4,117.97万元,增长61.56%,主要是受销售增加、利润增加影响;(4)支付其他与经营活动有关的现金增加3,360.76万元,增长32.82%,主要是销售费用、管理费用增加所致;(5)取得投资收益收到的现金增加272.6万元,增长100%,主要因为本期购买理财产品取得的收益,上年无此事项;(6)投资支付的现金增加22,290万元,增长100%,本期支出主要包括:本期将闲置资金投资理财,目前已累计投入18,300万元;对西藏日喀则地区天健医药有限公司投资支出990万元,对哈尔滨蒲公英药业有限公司投资支出3,000万元。(7)取得子公司及其他营业单位支付的现金净额减少1,326.05万元,下降100%,本期无该性质款项支出;(8)收到其他与筹资有关的现金增加3,533.67万元,增长967.94%,系收到募集资金专户定期存款利息增加所致;(9)偿还债务支付的现金增加250万元,增长100%。系本期广州新花城按合同约定偿还了3,000万元贷款中的250万元,上期无此事项;(10)分配股利、利润或偿付利息支付的现金减少6,871.90万元,下降97.91%,主要是本年无利润分红,该事项与同期对比减少7,000万元的流出。(二)重大事项进展情况及其影响和解决方案的分析说明1、非标意见情况□ 适用 √ 不适用2、公司存在向控股股东或其关联方提供资金、违反规定程序对外提供担保的情况□ 适用 √ 不适用4
       哈尔滨誉衡药业股份有限公司                                                 2012 年第三季度报告全文3、日常经营重大合同的签署和履行情况√ 适用 □ 不适用1、2008年6月,公司全资子公司经纬医药与澳诺中国和澳诺青岛在哈尔滨签订了《产品总经销协议》,协议约定,经纬医药取得2008年6月1日至2013年5月31日期间澳诺中国产品-注册商标为“金辛金丐特”的葡萄糖酸钙锌口服溶液的全国总经销权,保证金2,000万元。合同正在履行中。2、2008年8月,贵州汉方集团有限公司、贵州泛特尔生物技术有限公司(合称甲方)与公司下属的经纬医药(乙方)签署了《人神经生长因子注射液产品合作协议》,约定甲方授权乙方共同参与甲方生产的人神经生长因子注射液产品报批,乙方在甲方产品报批工作按协议进度完成后,有权获得人神经因子注射液500AU/2ml、1000AU/2ml的全国独家总经销商的权利;乙方代理期限为十年,自甲方获得生产批件后开始计算。合同正在履行中。3、2008年9月,贵州汉方集团有限公司、贵州泛特尔生物技术有限公司(合称甲方)与经纬医药(乙方)及自然人邓杰(丙方)签署了《人神经生长因子注射液产品合作补充协议》,约定将原协议中“乙方取得人神经生长因子注射液生产批件后一周内向甲方支付用于人神经生长因子注射液1000AU/2ml的保证金900万元”的内容变更为“乙方在签订本补充协议之日起一周内支付给甲方人神经生长因子注射液1000AU/2ml的保证金1,000万元”。甲乙丙一致同意,任何一方违反原协议和补充协议的约定,违约方将赔偿守约方全部经济损失并额外赔偿6,000万元违约金。合同正在履行中。4、公司与哈药集团生物工程有限公司签订了《前列地尔注射液总代理合同》。根据协议规定,本公司已支付哈药集团生物工程有限公司保证金2400万元,代理销售产品前列地尔注射液。目前协议规定的代理期限已经到期,经双方友好协商,达成一致意见,待双方市场交接完毕,哈药生物集团生物工程有限公司退还剩余代理保证金。截止2012年9月30日尚有38.23万代理保证金未退还。5、2010年7月,公司与上海东富龙科技股份有限公司签订设备订购合同,合同标的为冷冻干燥机及配套自动进出料系统等,合同价款2460万元人民币,截止2012年9月30日已按合同约定支付85%的合同价款2091万元人民币,设备在调试运行。合同正在履行中。6、为确保公司头孢米诺产品原料符合日本明治制果株式会社头孢米诺药品的检验标准及质量标准,同意公司与珠海傲华医药科技有限公司签订《技术使用许可协议》。协议签署后珠海傲华医药科技有限公司独家向公司提供头孢米诺原料的生产技术,并保证使用该技术生产所得产品符合日本明治制果株式会社头孢米诺药品的检验标准及质量标准,并对生产过程中出现的技术问题进行及时解决,该技术相关的合成路线、工艺、质量标准等技术秘密,不得以任何方式向第三方泄露或公开发表。合同正在履行中。7、2011年6月,公司与中电奥星制药系统工程有限公司签订安装工程合同,合同标的为108车间净化安装工程,合同价款2,064.85万元人民币,截止2012年9月30日已按合同约定支付合同价款1,652.34万元人民币,合同正在履行中。8、2011年9月14日,公司同日本明治制果株式会社就透明质酸钠产品合作意向达成一致,公司将在代理区域内销售透明质酸钠产品。9、2012年1月5日,公司同河南新帅克制药股份有限公司签订了硫酸氢氯吡格雷片(75mg)合作协议,协议约定关于协议产品合作事宜,对全国总经销权独家买断,买断金总金额为3,000万元,目前已付意向诚意金人民币3,000万元。3月23日该规格产品获得国家食品药品监督管理局颁发的生产批件。10、2012年2月27日,公司同美国坎伯兰制药公司签订了《布洛芬注射液和N-乙酰半胱氨酸注射液授权、销售和生产协议》。坎伯兰公司授予誉衡专有技术的独家许可,协议期间,誉衡在区域内进行生产、营销、经销、进口、宣传、推广和销售产品所合理需要的所有专有技术,并作为区域内的产品独家经销商、营销商、宣传商、推广商、进口商和销售商。协议从生效日期起至获得第一个产品生产批件后11年止。11、2012年1月12日公司与中科基业(北京)投资股份有限公司签订房屋租赁合同,租赁位于北京市海淀区学清路23号院1号楼汉华世纪大厦西楼(地上一层至五层,除保安室外),建筑面积9239.5平方米,拟作为誉衡嘉孕医疗投资有限公司经营场所。截止2012年9月30日,已预付相关房租及押金1476.17万元。合同正在履行中。12、2012年8月8日,公司同东亚制药公司签订了《技术许可协议》。协议期间,东亚授权誉衡独家许可。许可产品是指20mg及80mg或其他规格瓶装药物或包含多西他赛原料的制剂。本协议从生效日期(2012年8月9日)起至许可产品初次商业销售后第10年为止(“协议期限”)。协议期满后,此协议将自动更新延续一年,除非在自动更新开始前180天双方同意停止自动延续。4、其他√ 适用 □ 不适用1、2009 年 5 月,公司(甲方)与陕西西大科技园发展有限公司(乙方)签订了《技术转让合同》,双方协商约定,乙方已获得中药新药秦龙苦素及注射用秦龙苦素临床批件(批件号码分别为 2003L03259 和 2003L03260),乙方同意将秦龙苦素提取工艺的技术成果转让给甲方;2009 年 7 月 15 日,甲乙双方签订了《技术转让合同》,合同约定,在上述 2009 年 5 月 28日签订《技术转让合同》的基础上,乙方将秦龙苦素及注射用秦龙苦素新药项目的技术成果及与此相关的知识产权独家转让给甲方,使甲方拥有该项目的所有权。甲方需向乙方分四期支付 5,000 万元的技术转让费用。公司已支付了 2,500 万元技术转让费用,国家知识产权局已分别核准了将两项相关专利(专利号分别为 ZL200410073488.7 和 ZL03114558.2)的专利权人由5
          哈尔滨誉衡药业股份有限公司                                                 2012 年第三季度报告全文陕西西大科技园发展有限公司变更为本公司的申请。2、2010 年 11 月及 12 月,公司先后同化合物 SX004 及其衍生药物美迪替尼的实际所有权出让方上海一善投资管理有限公司及薛楚标签订了《关于化合物 SX004 及其衍生出来的药物美迪替尼实际所有权转让协议》,受让其分别持有标的 51%及 49%的所有权,标的转让价格分别是 3,500 万元及 3,000 万元,第三方王志林为上海一善履行协议提供担保,该次交易总计使用超额募集资金 6,500 万元。按照合同前期支付 4,460 万元。3、2011 年 9 月公司与明治公司签订了《协议书》、《技术合作合同》及《商标使用许可合同》,明治公司授权公司在中国大陆生产销售 0.5g 头孢米诺制剂时使用“美士灵”商标及产品名称,公司需向明治公司支付每支 2 元的技术及商标使用费用,上述协议有效期为 10 年。(三)公司或持股 5%以上股东在报告期内或持续到报告期内的承诺事项√ 适用 □ 不适用
                承诺事项                 承诺人        承诺内容        承诺时间        承诺期限    履行情况
    股改承诺
    收购报告书或权益变动报告书中所作
    承诺
    资产置换时所作承诺
                                                      公司股东恒
                                                      世达昌、誉衡
                                                      国际以及百
                                                      庚禹丰承诺:
                                                      自公司股票
                                                      上市之日起
                                                      三十六个月
                                                      内,不转让或
                                                      者委托他人
                                                      管理其持有
                                                      的发行人股
                                                      份,也不由发
                                                      行人回购其
                                       公司股东恒
                                                      持有的股份;
                                       世达昌、誉衡
                                                      公司实际控
                                       国际、百庚禹
                                                      制人朱吉满
                                       丰;公司实际
                                                      和白莉惠夫
                                       控制人朱吉
                                                      妇、公司副董   2010 年 06 月
    发行时所作承诺                     满和白莉惠                                    长期         履行中
                                                      事长王东绪     23 日
                                       夫妇、公司副
                                                      先生承诺:自
                                       董事长王东
                                                      公司股票在
                                       绪先生、公司
                                                      证券交易所
                                       董事总经理
                                                      上市之日起
                                       杨红冰先生。
                                                      三十六个月
                                                      内,不转让或
                                                      者委托他人
                                                      管理其持有
                                                      恒世达昌和
                                                      誉衡国际的
                                                      股份,也不由
                                                      恒世达昌和
                                                      誉衡国际回
                                                      购该部分股
                                                      份;公司董
                                                      事、总经理杨
                                                      红冰先生承6
          哈尔滨誉衡药业股份有限公司                                2012 年第三季度报告全文
                                                     诺:自公司股
                                                     票在证券交
                                                     易所上市之
                                                     日起三十六
                                                     个月内,不转
                                                     让或者委托
                                                     他人管理其
                                                     持有恒世达
                                                     昌的股份,也
                                                     不由恒世达
                                                     昌回购该部
                                                     分股份。朱吉
                                                     满先生、白莉
                                                     惠女士、王东
                                                     绪先生及杨
                                                     红冰先生还
                                                     承诺:在上述
                                                     承诺的限售
                                                     期届满后,在
                                                     担任公司董
                                                     事、监事或高
                                                     管人员期间,
                                                     每年转让的
                                                     股份不超过
                                                     所间接持有
                                                     公司股份总
                                                     数的 25%;离
                                                     职后半年内,
                                                     不转让所间
                                                     接持有的公
                                                     司股份。承诺
                                                     如果公司
                                                     2005 年度、
                                                     2006 年度按
                                                     照高新技术
                                                     企业税收优
                                                     惠政策所享
                                                     受的减按
                                                     15%的税率征
                                                     收企业所得
                                                     税的税收优
                                                     惠被认定无
                                                     效,本公司需
                                                     要补缴税金、
                                                     滞纳金、罚金
                                                     或承担其它
                                                     赔偿责任的,
                                                     将由恒世达
                                                     昌以及朱吉
                                                     满和白莉惠
                                                     夫妇向本公
                                                     司予以全额
                                                     补偿,并承担
                                                     连带责任。
    其他对公司中小股东所作承诺
    承诺是否及时履行                   √ 是 □ 否 □ 不适用
    未完成履行的具体原因及下一步计划   --7
          哈尔滨誉衡药业股份有限公司                                                 2012 年第三季度报告全文
    是否就导致的同业竞争和关联交易问
                                        □ 是 □ 否 √ 不适用
    题作出承诺
    承诺的解决期限                      --
    解决方式                            --
    承诺的履行情况                      --(四)对 2012 年度经营业绩的预计2012 年度预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形
    2012 年度归属于上市公司股东的净利润变动
                                                                       20%      至                         50%
    幅度
    2012 年度归属于上市公司股东的净利润变动
                                                                  14,021.79     至                    17,527.24
    区间(万元)
    2011 年度归属于上市公司股东的净利润(元)                                                     116,848,259.56
    业绩变动的原因说明                          加强公司主要产品的市场开拓力度,加强管理,稳步提高企业盈利能力。(五)其他需说明的重大事项1、证券投资情况□ 适用 √ 不适用2、衍生品投资情况□ 适用 √ 不适用3、报告期末衍生品投资的持仓情况□ 适用 √ 不适用4、报告期内接待调研、沟通、采访等活动登记表
                                                                                                谈论的主要内容
       接待时间          接待地点             接待方式       接待对象类型        接待对象
                                                                                                及提供的资料5、发行公司债券情况是否发行公司债券□ 是 √ 否四、附录(一)财务报表是否需要合并报表:√ 是 □ 否 □ 不适用8
          哈尔滨誉衡药业股份有限公司                                         2012 年第三季度报告全文如无特殊说明,财务报告中的财务报表的单位为:人民币元1、合并资产负债表编制单位: 哈尔滨誉衡药业股份有限公司
                                                                                                   单位: 元
                     项目                        期末余额                         期初余额
    流动资产:
        货币资金                                       1,323,766,202.71                 1,453,522,599.70
        结算备付金
        拆出资金
        交易性金融资产                                      183,000,000.00
        应收票据                                              6,241,188.99                     2,878,210.00
        应收账款                                             38,414,410.35                     3,188,085.06
        预付款项                                            225,788,030.90                   200,040,023.77
        应收保费
        应收分保账款
        应收分保合同准备金
        应收利息                                                                              20,250,000.00
        应收股利
        其他应收款                                           97,236,808.75                    66,997,538.18
        买入返售金融资产
        存货                                                 84,003,164.75                    72,473,723.73
        一年内到期的非流动资产
        其他流动资产
    流动资产合计                                       1,958,449,806.45                 1,819,350,180.44
    非流动资产:
        发放委托贷款及垫款
        可供出售金融资产
        持有至到期投资
        长期应收款
        长期股权投资                                          1,081,465.70                     1,081,465.70
        投资性房地产
        固定资产                                            225,089,462.02                   231,112,401.69
        在建工程                                            221,800,594.20                   142,033,720.63
        工程物资
        固定资产清理                                           163,314.32                          3,935.83
        生产性生物资产
        油气资产
        无形资产                                             64,168,479.01                    53,397,731.35
        开发支出                                             41,860,917.12                    25,024,418.04
        商誉                                                 34,169,999.58                    34,169,999.58
        长期待摊费用                                           577,850.30                      1,197,706.55
        递延所得税资产                                        3,821,756.94                     4,882,051.459
       哈尔滨誉衡药业股份有限公司                      2012 年第三季度报告全文
    其他非流动资产
    非流动资产合计                      592,733,839.19                492,903,430.82
    资产总计                           2,551,183,645.64              2,312,253,611.26流动负债:
    短期借款
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    交易性金融负债
    应付票据                          1,240,000.00                  7,200,500.00
    应付账款                         38,796,399.82                 30,416,277.20
    预收款项                          5,455,512.71                  2,184,297.89
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                        519,964.38                    949,659.87
    应交税费                            135,848.34                  8,765,723.55
    应付利息
    应付股利
    其他应付款                      180,503,482.58                 31,757,376.62
    应付分保账款
    保险合同准备金
    代理买卖证券款
    代理承销证券款
    一年内到期的非流动负债
    其他流动负债
    流动负债合计                        226,651,207.83                 81,273,835.13非流动负债:
    长期借款                         27,500,000.00                 30,000,000.00
    应付债券
    长期应付款
    专项应付款
    预计负债
    递延所得税负债                                                  3,037,500.00
    其他非流动负债                    1,396,000.00                    596,000.00
    非流动负债合计                       28,896,000.00                 33,633,500.00
    负债合计                            255,547,207.83                114,907,335.13所有者权益(或股东权益):
    实收资本(或股本)              280,000,000.00                280,000,000.00
    资本公积                       1,508,368,180.53             1,508,368,180.53
    减:库存股
    专项储备
    盈余公积                         52,355,305.31                 52,355,305.31
    一般风险准备10
       哈尔滨誉衡药业股份有限公司                                              2012 年第三季度报告全文
    未分配利润                                               426,613,588.62                   327,367,231.63
    外币报表折算差额
    归属于母公司所有者权益合计                              2,267,337,074.46                 2,168,090,717.47
    少数股东权益                                              28,299,363.35                    29,255,558.66
    所有者权益(或股东权益)合计                            2,295,636,437.81                 2,197,346,276.13
    负债和所有者权益(或股东权益)总计                      2,551,183,645.64                 2,312,253,611.26
    法定代表人:朱吉满                      主管会计工作负责人:杨华蓉                 会计机构负责人:赵金宇2、母公司资产负债表编制单位: 哈尔滨誉衡药业股份有限公司
                                                                                                     单位: 元
                  项目                             期末余额                         期初余额流动资产:
    货币资金                                            1,155,989,571.37                 1,276,562,458.86
    交易性金融资产                                           183,000,000.00
    应收票据                                                   3,562,451.14                     2,263,300.00
    应收账款                                                  37,257,507.04                     1,862,686.39
    预付款项                                                 202,846,829.96                   173,310,707.74
    应收利息                                                                                   20,250,000.00
    应收股利
    其他应收款                                                59,162,678.27                    49,843,273.54
    存货                                                      64,562,217.85                    59,119,171.45
    一年内到期的非流动资产
    其他流动资产
    流动资产合计                                            1,706,381,255.63                 1,583,211,597.98非流动资产:
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资                                             351,519,890.16                   291,519,890.16
    投资性房地产
    固定资产                                                 207,330,535.73                   212,840,827.75
    在建工程                                                 170,777,120.08                   102,922,574.33
    工程物资
    固定资产清理                                                163,314.32                          3,935.83
    生产性生物资产
    油气资产
    无形资产                                                  26,538,537.79                    22,820,251.31
    开发支出                                                  17,145,327.64                     8,821,800.98
    商誉
    长期待摊费用                                                466,782.51                       793,491.82
    递延所得税资产                                                76,081.24                     2,703,875.4511
       哈尔滨誉衡药业股份有限公司                                           2012 年第三季度报告全文
    其他非流动资产
    非流动资产合计                                            774,017,589.47               642,426,647.63
    资产总计                                                2,480,398,845.10              2,225,638,245.61流动负债:
    短期借款
    交易性金融负债
    应付票据                                                1,240,000.00                 7,200,500.00
    应付账款                                               52,998,794.86                26,202,988.73
    预收款项                                                2,061,214.82
    应付职工薪酬                                             218,935.56                     -57,765.64
    应交税费                                                2,135,513.22                 6,862,693.86
    应付利息
    应付股利
    其他应付款                                            158,994,505.26                10,857,204.22
    一年内到期的非流动负债
    其他流动负债
    流动负债合计                                              217,648,963.72                51,065,621.17非流动负债:
    长期借款
    应付债券
    长期应付款
    专项应付款
    预计负债
    递延所得税负债                                                                       3,037,500.00
    其他非流动负债
    非流动负债合计                                                                           3,037,500.00
    负债合计                                                  217,648,963.72                54,103,121.17所有者权益(或股东权益):
    实收资本(或股本)                                    280,000,000.00               280,000,000.00
    资本公积                                            1,508,119,070.29              1,508,119,070.29
    减:库存股
    专项储备
    盈余公积                                               52,355,305.31                52,355,305.31
    一般风险准备
    未分配利润                                            422,275,505.78               331,060,748.84
    外币报表折算差额
    所有者权益(或股东权益)合计                            2,262,749,881.38              2,171,535,124.44
    负债和所有者权益(或股东权益)总计                      2,480,398,845.10              2,225,638,245.61
    法定代表人:朱吉满                      主管会计工作负责人:杨华蓉              会计机构负责人:赵金宇3、合并本报告期利润表编制单位: 哈尔滨誉衡药业股份有限公司12
             哈尔滨誉衡药业股份有限公司                                2012 年第三季度报告全文
                                                                                             单位: 元
                    项目                   本期金额                         上期金额
    一、营业总收入                                       128,789,657.56                   119,510,628.32
        其中:营业收入                                128,789,657.56                   119,510,628.32
                利息收入
                已赚保费
                手续费及佣金收入
    二、营业总成本                                       104,130,527.96                   102,951,697.18
        其中:营业成本                                 50,387,137.40                    67,959,473.95
                利息支出
                手续费及佣金支出
                退保金
                赔付支出净额
                提取保险合同准备金净额
                保单红利支出
                分保费用
                营业税金及附加                          4,056,786.03                      812,275.30
                销售费用                               24,745,209.42                    11,636,848.43
                管理费用                               31,938,108.14                    24,468,321.37
                财务费用                               -7,269,566.72                    -2,076,312.89
                资产减值损失                             272,853.69                       151,091.02
    加    :公允价值变动收益(损失以“-”号填列)
                投资收益(损失以“-”号
                                                        1,841,265.36                      -328,297.96填列)
           其中:对联营企业和合营企
                                                                                          -328,297.96业的投资收益
                汇兑收益(损失以“-”号填列)
    三、营业利润(亏损以“-”号填列)                    26,500,394.96                    16,230,633.18
        加    :营业外收入                                 20,381.98                      143,759.92
        减    :营业外支出                                  5,289.08                     2,233,467.83
                其中:非流动资产处置损失                    5,289.08                        33,467.83四、利润总额(亏损总额以“-”号填
                                                       26,515,487.86                    14,140,925.27列)
        减:所得税费用                                  5,514,729.95                     2,519,855.99
    五、净利润(净亏损以“-”号填列)                    21,000,757.91                    11,621,069.28
        其中:被合并方在合并前实现的净利润
        归属于母公司所有者的净利润                     21,392,999.24                    11,621,069.28
        少数股东损益                                     -392,241.33
    六、每股收益:                               --                               --
        (一)基本每股收益                                      0.08                             0.04
        (二)稀释每股收益                                      0.08                             0.0413
          哈尔滨誉衡药业股份有限公司                                           2012 年第三季度报告全文七、其他综合收益
    八、综合收益总额                                              21,000,757.91                   11,621,069.28
        归属于母公司所有者的综合收益
                                                               21,392,999.24                   11,621,069.28总额
        归属于少数股东的综合收益总额                             -392,241.33本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0 元。
    法定代表人:朱吉满                       主管会计工作负责人:杨华蓉                会计机构负责人:赵金宇4、母公司本报告期利润表编制单位: 哈尔滨誉衡药业股份有限公司
                                                                                                    单位: 元
                  项目                              本期金额                        上期金额
    一、营业收入                                                  79,635,040.72                   52,739,054.75
        减:营业成本                                           16,402,913.68                   13,400,680.41
            营业税金及附加                                      3,615,817.19                     575,267.13
            销售费用                                           22,270,308.60                    4,204,127.33
            管理费用                                           23,162,951.92                   20,216,559.03
            财务费用                                           -6,516,541.91                   -1,760,191.88
            资产减值损失                                         122,476.69                       -13,778.84
    加:公允价值变动收益(损失以“-”号填列)
            投资收益(损失以“-”号填
                                                                1,450,493.16                     -328,297.96列)
         其中:对联营企业和合营企业
                                                                                                 -328,297.96的投资收益
    二、营业利润(亏损以“-”号填列)                            22,027,607.71                   15,788,093.61
        加:营业外收入                                            20,381.98                      143,759.92
        减:营业外支出                                              5,289.08                    2,233,467.83
            其中:非流动资产处置损失                                5,289.08                      33,467.83三、利润总额(亏损总额以“-”号填
                                                               22,042,700.61                   13,698,385.70列)
        减:所得税费用                                          4,418,928.98                    1,753,335.44
    四、净利润(净亏损以“-”号填列)                            17,623,771.63                   11,945,050.26
    五、每股收益:                                        --                              --
        (一)基本每股收益                                              0.06                            0.04
        (二)稀释每股收益                                              0.06                            0.04六、其他综合收益
    七、综合收益总额                                              17,623,771.63                   11,945,050.26
    法定代表人:朱吉满                       主管会计工作负责人:杨华蓉                会计机构负责人:赵金宇5、合并年初到报告期末利润表编制单位: 哈尔滨誉衡药业股份有限公司14
             哈尔滨誉衡药业股份有限公司                                2012 年第三季度报告全文
                                                                                             单位: 元
                    项目                   本期金额                         上期金额
    一、营业总收入                                       461,913,999.03                   374,477,462.20
        其中:营业收入                                461,913,999.03                   374,477,462.20
                利息收入
                已赚保费
                手续费及佣金收入
    二、营业总成本                                       343,705,238.07                   280,680,141.15
        其中:营业成本                                181,363,924.26                   192,745,549.07
                利息支出
                手续费及佣金支出
                退保金
                赔付支出净额
                提取保险合同准备金净额
                保单红利支出
                分保费用
                营业税金及附加                          8,323,437.19                     3,695,250.27
                销售费用                               88,879,136.71                    33,929,193.60
                管理费用                               87,588,228.03                    56,091,149.16
                财务费用                              -22,990,483.82                    -5,154,039.53
                资产减值损失                             540,995.70                       -626,961.42
    加    :公允价值变动收益(损失以“-”号填列)
                投资收益(损失以“-”号
                                                        2,726,024.49                    -1,257,974.61填列)
           其中:对联营企业和合营企
                                                                                        -1,257,974.61业的投资收益
                汇兑收益(损失以“-”号填列)
    三、营业利润(亏损以“-”号填列)                   120,934,785.45                    92,539,346.44
        加    :营业外收入                                 47,708.00                      186,929.92
        减    :营业外支出                               109,924.91                      2,342,266.67
                其中:非流动资产处置损失                    9,224.91                        42,266.67四、利润总额(亏损总额以“-”号填
                                                      120,872,568.54                    90,384,009.69列)
        减:所得税费用                                 22,582,406.86                    14,878,980.65
    五、净利润(净亏损以“-”号填列)                    98,290,161.68                    75,505,029.04
        其中:被合并方在合并前实现的净利润
        归属于母公司所有者的净利润                     99,246,356.99                    75,505,029.04
        少数股东损益                                     -956,195.31
    六、每股收益:                               --                               --
        (一)基本每股收益                                      0.35                             0.27
        (二)稀释每股收益                                      0.35                             0.2715
          哈尔滨誉衡药业股份有限公司                                             2012 年第三季度报告全文七、其他综合收益
    八、综合收益总额                                               98,290,161.68                     75,505,029.04
        归属于母公司所有者的综合收益
                                                                99,246,356.99                     75,505,029.04总额
        归属于少数股东的综合收益总额                              -956,195.31年初到报告期末发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0 元。
    法定代表人:朱吉满                       主管会计工作负责人:杨华蓉                  会计机构负责人:赵金宇6、母公司年初到报告期末利润表编制单位: 哈尔滨誉衡药业股份有限公司
                                                                                                       单位: 元
                  项目                              本期金额                          上期金额
    一、营业收入                                                  296,591,913.80                    181,738,979.83
        减:营业成本                                            62,222,450.94                     46,034,003.48
            营业税金及附加                                       6,829,892.98                      2,388,383.71
            销售费用                                            69,758,657.46                     13,024,739.50
            管理费用                                            69,654,309.21                     44,469,007.29
            财务费用                                           -20,388,603.35                     -4,689,746.05
            资产减值损失                                          287,329.79                            -564.55
    加:公允价值变动收益(损失以“-”号填列)
            投资收益(损失以“-”号填
                                                                 2,035,690.79                     51,687,561.14列)
         其中:对联营企业和合营企业
                                                                                                  -1,257,974.61的投资收益
    二、营业利润(亏损以“-”号填列)                            110,263,567.56                    132,200,717.59
        加:营业外收入                                              36,894.00                       201,554.40
        减:营业外支出                                            109,224.91                       2,342,266.67
            其中:非流动资产处置损失                                 9,224.91                         42,266.67三、利润总额(亏损总额以“-”号填
                                                               110,191,236.65                    130,060,005.32列)
        减:所得税费用                                          18,976,479.71                      9,818,430.73
    四、净利润(净亏损以“-”号填列)                             91,214,756.94                    120,241,574.59
    五、每股收益:                                        --                                --
        (一)基本每股收益                                               0.33                              0.43
        (二)稀释每股收益                                               0.33                              0.43六、其他综合收益
    七、综合收益总额                                               91,214,756.94                    120,241,574.59
    法定代表人:朱吉满                       主管会计工作负责人:杨华蓉                  会计机构负责人:赵金宇7、合并年初到报告期末现金流量表编制单位: 哈尔滨誉衡药业股份有限公司16
        哈尔滨誉衡药业股份有限公司                                2012 年第三季度报告全文
                                                                                        单位: 元
                项目                  本期金额                         上期金额一、经营活动产生的现金流量:
      销售商品、提供劳务收到的现金               642,003,520.44                   430,702,829.21
      客户存款和同业存放款项净增加额
      向中央银行借款净增加额
      向其他金融机构拆入资金净增加额
      收到原保险合同保费取得的现金
      收到再保险业务现金净额
      保户储金及投资款净增加额
      处置交易性金融资产净增加额
      收取利息、手续费及佣金的现金
      拆入资金净增加额
      回购业务资金净增加额
      收到的税费返还
      收到其他与经营活动有关的现金                43,213,036.85                    74,540,306.62
    经营活动现金流入小计                            685,216,557.29                   505,243,135.83
      购买商品、接受劳务支付的现金               218,831,321.96                   258,934,268.01
      客户贷款及垫款净增加额
      存放中央银行和同业款项净增加额
      支付原保险合同赔付款项的现金
      支付利息、手续费及佣金的现金
      支付保单红利的现金
      支付给职工以及为职工支付的现
                                                  46,898,818.07                    36,525,026.59金
      支付的各项税费                             108,073,924.21                    66,894,235.81
      支付其他与经营活动有关的现金               136,001,958.03                   102,394,406.38
    经营活动现金流出小计                            509,806,022.27                   464,747,936.79
    经营活动产生的现金流量净额                      175,410,535.02                    40,495,199.04二、投资活动产生的现金流量:
      收回投资收到的现金
      取得投资收益所收到的现金                     2,726,024.49
    处置固定资产、无形资产和其他长
                                                      29,640.00                        75,459.00期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
      收到其他与投资活动有关的现金
    投资活动现金流入小计                              2,755,664.49                        75,459.00
    购建固定资产、无形资产和其他长
                                                 120,038,000.51                   109,618,000.20期资产支付的现金
      投资支付的现金                             222,900,000.00
      质押贷款净增加额17
          哈尔滨誉衡药业股份有限公司                                            2012 年第三季度报告全文
    取得子公司及其他营业单位支付
                                                                                                 13,260,512.47的现金净额
        支付其他与投资活动有关的现金
    投资活动现金流出小计                                          342,938,000.51                   122,878,512.67
    投资活动产生的现金流量净额                                -340,182,336.02                  -122,803,053.67三、筹资活动产生的现金流量:
        吸收投资收到的现金
    其中:子公司吸收少数股东投资收到的现金
        取得借款收到的现金
        发行债券收到的现金
        收到其他与筹资活动有关的现金                            38,987,421.29                     3,650,708.08
    筹资活动现金流入小计                                           38,987,421.29                     3,650,708.08
        偿还债务支付的现金                                       2,500,000.00
        分配股利、利润或偿付利息支付的
                                                                 1,468,969.26                    70,187,966.09现金
    其中:子公司支付给少数股东的股利、利润
        支付其他与筹资活动有关的现金                                 3,048.02
    筹资活动现金流出小计                                            3,972,017.28                    70,187,966.09
    筹资活动产生的现金流量净额                                     35,015,404.01                   -66,537,258.01四、汇率变动对现金及现金等价物的影
                                                                                                      1,843.98响
    五、现金及现金等价物净增加额                              -129,756,396.99                  -148,843,268.66
        加:期初现金及现金等价物余额                      1,453,522,599.70                 1,538,322,600.66
    六、期末现金及现金等价物余额                             1,323,766,202.71                 1,389,479,332.00
    法定代表人:朱吉满                       主管会计工作负责人:杨华蓉                 会计机构负责人:赵金宇8、母公司年初到报告期末现金流量表编制单位: 哈尔滨誉衡药业股份有限公司
                                                                                                      单位: 元
                  项目                              本期金额                         上期金额一、经营活动产生的现金流量:
        销售商品、提供劳务收到的现金                           434,077,581.68                   219,100,459.36
        收到的税费返还
        收到其他与经营活动有关的现金                             2,665,753.59                     3,872,180.58
    经营活动现金流入小计                                          436,743,335.27                   222,972,639.94
        购买商品、接受劳务支付的现金                            67,528,855.49                    83,379,811.96
        支付给职工以及为职工支付的现
                                                                27,337,066.08                    21,804,392.57金
        支付的各项税费                                          91,352,955.95                    46,533,373.11
        支付其他与经营活动有关的现金                            54,372,700.22                    24,398,767.10
    经营活动现金流出小计                                          240,591,577.74                   176,116,344.7418
          哈尔滨誉衡药业股份有限公司                                          2012 年第三季度报告全文
    经营活动产生的现金流量净额                                 196,151,757.53                  46,856,295.20二、投资活动产生的现金流量:
        收回投资收到的现金
        取得投资收益所收到的现金                              2,035,690.79                  52,945,535.75
    处置固定资产、无形资产和其他长
                                                                 29,640.00                      75,459.00期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
        收到其他与投资活动有关的现金
    投资活动现金流入小计                                         2,065,330.79                  53,020,994.75
    购建固定资产、无形资产和其他长
                                                             82,253,808.36                  99,253,271.26期资产支付的现金
        投资支付的现金                                      282,900,000.00                 115,150,000.00
    取得子公司及其他营业单位支付的现金净额
        支付其他与投资活动有关的现金
    投资活动现金流出小计                                       365,153,808.36                 214,403,271.26
    投资活动产生的现金流量净额                                -363,088,477.57                -161,382,276.51三、筹资活动产生的现金流量:
        吸收投资收到的现金
        取得借款收到的现金
        发行债券收到的现金
        收到其他与筹资活动有关的现金                         68,995,076.73                  63,650,708.08
    筹资活动现金流入小计                                        68,995,076.73                  63,650,708.08
        偿还债务支付的现金
        分配股利、利润或偿付利息支付的
                                                                                            70,187,966.09现金
        支付其他与筹资活动有关的现金                         22,631,244.18                  38,029,653.37
    筹资活动现金流出小计                                        22,631,244.18                 108,217,619.46
    筹资活动产生的现金流量净额                                  46,363,832.55                  -44,566,911.38四、汇率变动对现金及现金等价物的影
                                                                                                 2,520.04响
    五、现金及现金等价物净增加额                              -120,572,887.49                -159,090,372.65
        加:期初现金及现金等价物余额                      1,276,562,458.86                1,431,088,155.41
    六、期末现金及现金等价物余额                             1,155,989,571.37                1,271,997,782.76
    法定代表人:朱吉满                       主管会计工作负责人:杨华蓉                会计机构负责人:赵金宇(二)审计报告
    审计意见                    未经审计审计报告正文
                                                                             哈尔滨誉衡药业股份有限公司19
    哈尔滨誉衡药业股份有限公司   2012 年第三季度报告全文
                                   法定代表人:朱吉满 先生
                                    二〇一二年十月二十九日20